Massimiliano Mirabella

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number ofKpnI repeats at the 4q35 locus and clinical phenotype

Enzo Ricci, Giuliana Galluzzi, Giancarlo Deidda et al. · Annals of Neurology · 1999 · 296 citations

Ecori Fragment Size, Rare Diseases, Facioscapulohumeral Muscular Dystrophy +15

The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low‐dose aspirin in patients with and without diabetes

Bianca Rocca, Francesca Santilli, Dario Pitocco et al. · Journal of Thrombosis and Haemostasis · 2012 · 245 citations · Full text

Thrombosis, Diabetes Management, Cardiovascular Disease +9

Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression

Mario Pescatori, Aldobrando Broccolini, Carlo Minetti et al. · The FASEB Journal · 2007 · 244 citations

Muscle Function, Engineering, Genetics +17

Enhanced Dystrophic Progression in mdx Mice by Exercise and Beneficial Effects of Taurine and Insulin-Like Growth Factor-1

Annamaria De Luca, Sabata Pierno, Antonella Liantonio et al. · Journal of Pharmacology and Experimental Therapeutics · 2003 · 206 citations